Addressing Toxicities in CAR T-Cell Therapy

Video content above is prompted by the following:

1. Dr. O’Dwyer to Dr. Molina: What are future directions or remaining unmet needs for CAR T-cell therapy in R/R B-cell ALL? 
2. Resource links: Roddie C et al. Risk factors associated with sub-optimal outcomes following obe-cel: what we have learned from the FELIX trial. ASH 2024 poster abstract or see Appendix 7
3. Dr. O’Dwyer to Dr. Molina: As we know, CRS and ICANS are associated with CAR T-cell therapies, Dr Molina: Are there risk factors that can predict those who are at higher risk for developing severe CRS and/or ICANs?